Q2 2026 Charles River Laboratories International Inc Earnings Call Transcript

Aug 5, 2026 / 01:00 PM GMT

Release Date Price: €202.7 (-0.44%)

Transcript 10-Q8-K

Key Points

Positve

Charles River Laboratories International Inc (CRL) exceeded its second-quarter financial targets, with organic revenue growth of 0.1%, the first improvement since Q3 2023, and raised its full-year guidance.
The DSA segment showed strong demand recovery, with a net book-to-bill of 1.19x, the highest in nearly four years, and the third consecutive quarter above 1.0x, indicating robust future revenue.
Strategic portfolio refinements, including divestitures of CDMO and certain European sites, drove a 420 basis point sequential operating margin improvement to 20.5% and are expected to contribute to at least 500 basis points of margin expansion in the second half.
The acquisition of the Cambodian NHP supplier is expected to lower sourcing costs, providing a significant margin benefit in Q4 and a competitive advantage in NHP-related safety assessment studies.
The company is investing in growth areas like bioanalysis and digital pathology, and has formed key collaborations with Eli Lilly and Aravela Therapeutics, positioning it for future innovation and client-centric growth.
Biopharma demand is sustainably improving, supported by strong biotech funding of nearly $100 billion, leading to increased bookings and proposal activity across both small/mid-sized biotech and global biopharma clients.

Negative

The RMS segment continues to face headwinds, with organic revenue declining 1.4% in Q2, driven by lower volumes in North America and constrained spending from academic and government clients due to flat NIH budgets.
The DSA segment's year-over-year operating margin declined by 180 basis points in Q2 due to higher study-related direct costs, though this is expected to improve in the coming quarters.
The company faces a higher non-GAAP tax rate for the year, increased by approximately 100 basis points to 23%-24%, due to proposed tax legislation changes in a foreign jurisdiction, creating a $0.20 EPS headwind.
Unallocated corporate costs were higher than expected in Q2, totaling $72 million or 7.2% of revenue, driven by increased deferred compensation plan costs, and the full-year outlook for these costs was raised to 6.0% of revenue.
The recovery in the DSA segment is expected to be gradual, with organic growth only projected at low single digits for 2026, as it takes several quarters for bookings to convert into revenue.
Pricing in the market has not yet materially improved, remaining stable, and any potential pricing uptick is not expected to flow through to revenue until 2027.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CRL.N - Charles River Laboratories International, Inc.
Q2 2026 Charles River Laboratories International Inc Earnings Call
Aug 05, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, thank you for standing by and welcome to the Charles River Laboratories Second Quarter 2026 Earnings Conference Call.

This call is being recorded.

At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session.

To ask a question during this period, you will need to press *1 on your telephone keypad.

If you want to remove yourself from the queue, please press *2. Lastly, if you should require operator assistance, please press *0. I would now like to turn the conference over to our host, Todd Spencer, Vice President of Investor Relations.

Please go

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.